Gilead didnt rush to buy Tubulis. It paid $50M in 2024 for an exclusive look at clinical data, watched TUB-040 post a 59% response rate at ESMO, then spent 14 months deciding whether the $3.15B price tag was worth it. That option structure not a bidding war is the real story.
image from grok
Gilead Sciences paid $50 million in December 2024 for an option to acquire Tubulis after reviewing its ADC platform, exercising that option in 2026 for $3.15 billion plus up to $1.85 billion in milestones after seeing a 59% overall response rate in platinum-resistant ovarian cancer. The deal structure—paying upfront for the right to review clinical data before committing—appears designed to avoid a repeat of Gilead's costly 2020 Immunomedics acquisition ($21 billion), where the flagship ADC Trodelvy later failed in lung cancer and was withdrawn from bladder cancer. The transaction reflects Big Pharma's continued aggressive pursuit of ADC assets, with the market projected to nearly double from $15.4 billion in 2026 to $35 billion by 2034.
ARTICLE BODY ---
Gilead Sciences is buying Tubulis for up to $5 billion — the company's third acquisition in the first four months of 2026. But unlike a typical bidding war between pharmaceutical giants, this deal has a paper trail that shows exactly how a large biotech player managed risk in one of the most crowded corners of oncology.
In December 2024, Gilead paid Tubulis $20 million upfront plus a $30 million option fee for the exclusive right to acquire the German biotech after reviewing its clinical data. The arrangement gave Gilead a choice: exercise the option after seeing the numbers, or walk away. What Gilead saw was an overall response rate (ORR) of 59% in platinum-resistant ovarian cancer — a patient population that has run out of standard treatment options — and the company exercised. The result is a $3.15 billion cash commitment, with up to another $1.85 billion in contingent payments if development milestones are hit.
The price tag is large. But so is the ceiling. Antibody-drug conjugates, which link a targeted toxin to a monoclonal antibody that guides it to tumor cells, have become one of oncology's most valuable drug classes. AstraZeneca and Daiichi Sankyo's ADC Enhertu generated nearly $3.8 billion in sales in 2024, a 50% jump from the year before, and reshaped how several types of breast cancer are treated. The global ADC market is projected to grow from $15.4 billion in 2026 to nearly $35 billion by 2034, according to Straits Research. Big pharma has taken note. AbbVie agreed to buy ImmunoGen for $10.1 billion in January 2024; the deal closed in February 2024. Pfizer acquired Seagen for $43 billion in December 2023.
Gilead's own track record in ADCs is instructive. The company acquired Immunomedics for $21 billion in 2020 — its largest deal ever — primarily for Trodelvy, an ADC that was later withdrawn from the bladder cancer market and failed a late-stage trial in lung cancer. The bet on Tubulis looks like an attempt to avoid a repeat of that expensive miscalculation. By paying $50 million upfront for an option rather than buying blind, Gilead got 14 months of clinical data before committing. The ESMO Congress 2025 readout, showing a 59% response rate in 67 patients with platinum-resistant ovarian cancer, is what turned the option into a deal.
Tubulis, which spun out of the Leibniz-FMP research institute in Germany, raised a $361 million Series C in October 2025 — the largest ever for a European biotech and the largest ever for a private ADC developer globally. That raise happened while Gilead's option was active, which meant Tubulis had negotiating leverage most early-stage biotechs don't have. A company with a live partnership deal and a landmark Series C doesn't need to give away the company at the first offer. Gilead had to make the data worth exercising.
The market was down sharply in 2025, Dominik Schumacher, Tubulis's co-founder and CEO, said at the time of the Series C, referring to oncology VC funding, which fell to roughly $810 million from nearly $5 billion in 2024. "We had strong Phase I data and chose to fundraise rather than take a discounted deal." The October 2025 raise gave Tubulis a post-option valuation that likely set a floor for Gilead's eventual buyout price.
TUB-040, the lead asset, targets NaPi2b, an antigen expressed in ovarian cancer and lung adenocarcinomas. The 59% ORR figure came from a Phase I/IIa trial with 67 evaluable patients as of September 2025, with responses ranging from 50% to 67% across dose cohorts; the confirmed ORR was 50%. The drug received FDA Fast Track designation in June 2024, which accelerates the regulatory review timeline. A second asset, TUB-030, targeting a different antigen called 5T4, is in a Phase 1 trial for solid tumors under a Bristol Myers Squibb partnership.
One caution sits underneath the headline number. Mersana Therapeutics failed a NaPi2b-targeting ADC in July 2023 when the UPLIFT study missed its endpoint — the same target as TUB-040. Mersana's drug used a different linker and payload chemistry, and Tubulis's phosphorus-based linker platform is designed to address stability issues that plagued earlier generations of the technology. But the Mersana failure is a reminder that a good target and a good response rate in Phase I don't guarantee a registrational path. The chemistry underneath the antibody matters as much as the antigen on the surface.
The deal is expected to close in Q2 2026. Gilead's executive vice president of research, Flavius Martin, will oversee integration of Tubulis into the company's oncology pipeline.
For Gilead, the question is whether TUB-040 can replicate those early response rates in a larger registrational trial and whether the platform can produce more than one viable drug. For the broader ADC field, the deal signals that large pharma is willing to pay for validated clinical data rather than betting on pre-clinical biology. Buying biotech on potential is still common. But Gilead just demonstrated that the price of an option is a very different kind of discipline than the price of a buyout.
Story entered the newsroom
Assigned to reporter
Research completed — 8 sources registered. Gilead buys Tubulis for $3.15B cash (up to $5B total), third acquisition of 2026. The angle: Gilead paid $50M in December 2024 for an exclusive option
Draft (828 words)
Reporter revised draft (828 words)
Reporter revised draft (835 words)
Reporter revised draft based on fact-check feedback
Reporter revised draft based on editorial feedback (836 words)
Approved for publication
Published (841 words)
Get the best frontier systems analysis delivered weekly. No spam, no fluff.
Biotech & Life Sciences · 3h 28m ago · 3 min read
Biotech & Life Sciences · 3h 44m ago · 4 min read
